Clinical Trial for Obesity and Obesity-related Medical Conditions.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Obesity and Obesity-related Medical Conditions

Sex

Male or Female

Age

18 - 75 years

Healthy participants

Eligibility criteria

Inclusion criteria

BMI ≥27 kg/m2 and ≤38.0 kg/m2 (inclusive) at screening
For participants in Part A and B, no history of clinically significant diseases or clinically significant findings from the physical examination. For participants in Part C, no clinically significant diseases except T2DM, well controlled hypertension, and/or dyslipidemia.
For participants in Part C, diagnosed with T2DM for at least 3 months before screening.
For participants in Part C, T2DM includes glycated hemoglobin (HbA1c) value ≤10.5% at Screening and treated with stable therapy for at least 30 days prior to Screening/Visit 1.

Exclusion criteria

Female who is lactating or who is pregnant according to the pregnancy test at Screening or on Day 1.
Seated blood pressure higher than 160/100 mmHg at the Screening visit or prior to the first study drug administration.
Elevated resting pulse greater than 100 beats per minute at Screening visit or prior to the first study drug administration.
Estimated glomerular filtration rate (eGFR) <80 mL/min at the Screening visit.
Diagnosis of Type 1 diabetes.
For Part A and Part B: Diagnosis of T2DM or glycated hemoglobin (HbA1c) > 6.4% or fasting plasma glucose >126 mg/dL at the Screening visit or history of taking any medications to lower glucose.
For Part A and Part B: Participant reported weight-related comorbidity, including sleep apnea and cardiovascular disease.
History of bariatric or weight loss surgeries.
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome.
Lifetime history of acute or chronic pancreatitis or pancreatic cancer.
Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration or plans to do so.

Study overview

This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

View locations for this study

Find the closest location, your results will be shown below

Find the closest location

Miles

0500

Nearest Locations found

1 site found

Research Site MET233/097 24-101-001

Cypress, California, United States, 90630

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Recruitment Status
Site details
Study Contact
Clinical Trials ID

Join PfizerConnect

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Join PfizerConnect

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?